The Brussels stock exchange showed signs of recovery on Friday after experiencing losses over the previous three trading days, with the Bel20 index rising by 0.35% to 4,374.2 points.
Argenx led the gains among index stocks, rebounding 2% to €496.
UCB saw progress, rising 1.78% to a closing price of 154.4 euros, after receiving approval to market its drug, Rystiggo, for home administration in Japan.
Cofinimmo increased by 0.45% to €77.6, while dismissing Aedifica’s offer, which dropped 1.40% to 66.90 euros, citing that it undervalues the company and poses execution risks.
In the broader market, Avantium surged by 8.49% to €1.1.
VGP climbed 3.17% to €81.3, having secured annual rental income contracts worth 431.8 million euros by the end of April and acquired its first development land in the UK.
Bpost rose by 2.64% to €1.4, largely driven by its acquisition of the French parcel service, Staci, though its adjusted operating profit fell to €41.6 million.
Montea advanced 1.68% to €65.4, maintaining its target of a year-end net recurring profit of €4.9 per share.
Proximus edged up by 0.46% to €6.5, with a notable increase of 39.4% in net profit for the first quarter, reaching €140 million.
GBL experienced a significant decline, falling by 3.92% to €69.9 after distributing a five-euro dividend.
Sofina limited its losses to 0.24% at €248.2, attributing the decline in its intrinsic value to a weakening US dollar and dividend debt impacts.
On the second tier, Fluxys Belgium dropped by 2.78% to €21.
